TR1801-ADC

News alerts, weekly reports and conference planners

Company:

Mitsubishi Tanabe, Open Innovation Partners

Drug class:

DNA replication inhibitor, c-MET-targeted antibody-drug conjugate

Related drugs:

‹

›

MET overexpression	Pancreatic Cancer	MET overexpression	Pancreatic Cancer	TR1801-ADC Sensitive: D – Preclinical TR1801-ADC Sensitive : D	TR1801-ADC Sensitive: D – Preclinical TR1801-ADC Sensitive : D
MET underexpression	Solid Tumor	MET underexpression	Solid Tumor	TR1801-ADC Sensitive: D – Preclinical TR1801-ADC Sensitive : D	TR1801-ADC Sensitive: D – Preclinical TR1801-ADC Sensitive : D

Associations
(2)